The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

Atraverse Medical has raised $29.4 million to fund its minimally invasive system for accessing the inner chambers of the ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...